%PDF-1.6
%
1 0 obj
<<
/Lang (en)
/MarkInfo <<
/Marked true
>>
/Metadata 2 0 R
/Outlines 3 0 R
/PageLayout /OneColumn
/PageMode /UseOutlines
/Pages 4 0 R
/StructTreeRoot 5 0 R
/Type /Catalog
/ViewerPreferences <<
/DisplayDocTitle true
>>
>>
endobj
6 0 obj
<<
/Author (Gemeinsamer Bundesausschuss/Federal Joint Committee \(g-ba.de\))
/Category ()
/Comments ()
/Company ()
/CreationDate (D:20220901112232+02'00')
/Creator <4163726F626174205044464D616B65722032302066FC7220576F7264>
/Keywords <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>
/Manager ()
/ModDate (D:20220902090136+02'00')
/Producer (Adobe PDF Library 20.5.173)
/SourceModified (D:20220823132430)
/Subject (Pharmaceuticals Directive:)
/Title (Resolution)
/_DocHome (1460877555)
>>
endobj
2 0 obj
<<
/Length 5266
/Subtype /XML
/Type /Metadata
>>
stream
2022-09-02T09:01:36+02:00
2022-09-01T11:22:32+02:00
2022-09-02T09:01:36+02:00
Acrobat PDFMaker 20 für Word
uuid:a1d9daa4-ed22-454e-bd45-e6804d948869
uuid:e5504f08-cae3-4158-ae63-0d5d8eaf8ba6
15
application/pdf
Resolution
Pharmaceuticals Directive:
Gemeinsamer Bundesausschuss/Federal Joint Committee (g-ba.de)
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Ivacaftor/ Tezacaftor/ Elexacaftor (new therapeutic indication: Cystic Fibrosis
combination regimen with ivacaftor
6 to 11 years (heterozygous for F508del and RF mutations))
Adobe PDF Library 20.5.173
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Ivacaftor/ Tezacaftor/ Elexacaftor (new therapeutic indication: Cystic Fibrosis, combination regimen with ivacaftor, 6 to 11 years (heterozygous for F508del and RF mutations))
D:20220823132430
1460877555
Arzneimittel-Richtlinie: Anlage XII â•fi Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V
endstream
endobj
3 0 obj
<<
/Count 9
/First 7 0 R
/Last 8 0 R
/Type /Outlines
>>
endobj
4 0 obj
<<
/Count 5
/Kids [9 0 R 10 0 R 11 0 R 12 0 R 13 0 R]
/Type /Pages
>>
endobj
5 0 obj
<<
/K 14 0 R
/ParentTree 15 0 R
/ParentTreeNextKey 10
/RoleMap 16 0 R
/Type /StructTreeRoot
>>
endobj
7 0 obj
<<
/A 17 0 R
/Next 18 0 R
/Parent 3 0 R
/Title (Resolution)
>>
endobj
8 0 obj
<<
/A 19 0 R
/Parent 3 0 R
/Prev 20 0 R
/Title (II. The resolution will enter into force on the day of its publication on the website of the G-BA on 4 August 2022.)
>>
endobj
9 0 obj
<<
/Contents [21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 30 0 R
/TT1 31 0 R
/TT2 32 0 R
>>
/XObject <<
/OL1 33 0 R
>>
>>
/Rotate 0
/StructParents 0
/Tabs /S
/Type /Page
>>
endobj
10 0 obj
<<
/Contents [34 0 R 35 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 30 0 R
/TT1 31 0 R
/TT2 32 0 R
/TT3 36 0 R
>>
/XObject <<
/OL1 33 0 R
>>
>>
/Rotate 0
/StructParents 1
/Tabs /S
/Type /Page
>>
endobj
11 0 obj
<<
/Annots [37 0 R 38 0 R 39 0 R]
/Contents [40 0 R 41 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/C2_0 42 0 R
/C2_1 43 0 R
/TT0 30 0 R
/TT1 31 0 R
/TT2 36 0 R
/TT3 32 0 R
>>
/XObject <<
/OL1 33 0 R
>>
>>
/Rotate 0
/StructParents 2
/Tabs /S
/Type /Page
>>
endobj
12 0 obj
<<
/Contents [44 0 R 45 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 30 0 R
/TT1 31 0 R
/TT2 32 0 R
/TT3 36 0 R
>>
/XObject <<
/OL1 33 0 R
>>
>>
/Rotate 0
/StructParents 5
/Tabs /S
/Type /Page
>>
endobj
13 0 obj
<<
/Annots [46 0 R 47 0 R]
/Contents [48 0 R 49 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 30 0 R
/TT1 31 0 R
/TT2 32 0 R
>>
/XObject <<
/OL1 33 0 R
>>
>>
/Rotate 0
/StructParents 6
/Tabs /S
/Type /Page
>>
endobj
14 0 obj
<<
/K [50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R 59 0 R
60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R 69 0 R
70 0 R 71 0 R 72 0 R 73 0 R 74 0 R 75 0 R 76 0 R 77 0 R 78 0 R 79 0 R
80 0 R 81 0 R 82 0 R 83 0 R 84 0 R 85 0 R 86 0 R 87 0 R 88 0 R 89 0 R
90 0 R 91 0 R 92 0 R 93 0 R 94 0 R 95 0 R 96 0 R 97 0 R 98 0 R 99 0 R
100 0 R 101 0 R 102 0 R 103 0 R 104 0 R 105 0 R 106 0 R]
/P 5 0 R
/S /Sect
>>
endobj
15 0 obj
<<
/Nums [0 [50 0 R 51 0 R 52 0 R 53 0 R 54 0 R 55 0 R 56 0 R 57 0 R 58 0 R]
1 [59 0 R 60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R 66 0 R 67 0 R 68 0 R
69 0 R 70 0 R 71 0 R 72 0 R 73 0 R 74 0 R 75 0 R 76 0 R]
2 [77 0 R 79 0 R 80 0 R 81 0 R null 107 0 R null 108 0 R null null
109 0 R null 110 0 R null 111 0 R null null 112 0 R null 113 0 R
null 114 0 R null 115 0 R null 116 0 R 117 0 R 118 0 R null 119 0 R
null 120 0 R 121 0 R 122 0 R null 123 0 R null 124 0 R 125 0 R 126 0 R
null 127 0 R null 128 0 R 129 0 R 130 0 R null 131 0 R null 132 0 R
null 133 0 R null 134 0 R null 135 0 R null 136 0 R null 137 0 R
null 138 0 R null 139 0 R 83 0 R 84 0 R 85 0 R 86 0 R 87 0 R 88 0 R
89 0 R null 140 0 R 90 0 R null 141 0 R null 142 0 R 77 0 R]
3 140 0 R 4 140 0 R
5 [91 0 R 92 0 R 93 0 R 94 0 R 95 0 R null 143 0 R null 144 0 R null
null 145 0 R null 146 0 R null 147 0 R null 148 0 R null 149 0 R
null 150 0 R null 151 0 R null 152 0 R 153 0 R null 154 0 R null
155 0 R 156 0 R null 157 0 R null 158 0 R 159 0 R null 160 0 R null
161 0 R null 162 0 R null 163 0 R null 164 0 R 165 0 R null 166 0 R
null 167 0 R 168 0 R null 169 0 R null 170 0 R 171 0 R 97 0 R 98 0 R
99 0 R 100 0 R]
6 [101 0 R 102 0 R 172 0 R 102 0 R 103 0 R 104 0 R 105 0 R 106 0 R]
7 172 0 R 8 172 0 R 9 142 0 R]
>>
endobj
16 0 obj
<<
/Annotation /Span
/Artifact /P
/Bibliography /BibEntry
/Chart /Figure
/Diagram /Figure
/DropCap /Figure
/Endnote /Note
/Footnote /Note
/InlineShape /Figure
/Outline /Span
/Strikeout /Span
/Subscript /Span
/Superscript /Span
/TextBox /Art
/Underline /Span
>>
endobj
17 0 obj
<<
/D [9 0 R /XYZ 69 743 0.0]
/S /GoTo
>>
endobj
18 0 obj
<<
/A 173 0 R
/Next 174 0 R
/Parent 3 0 R
/Prev 7 0 R
/Title (of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive:)
>>
endobj
19 0 obj
<<
/D [13 0 R /XYZ 69 743 0.0]
/S /GoTo
>>
endobj
20 0 obj
<<
/A 175 0 R
/Count 4
/First 176 0 R
/Last 177 0 R
/Next 8 0 R
/Parent 3 0 R
/Prev 174 0 R
/Title (I. In Annex XII, the following information shall be added after No. 4 to the information on the benefit assessment of Ivacaftor/ Tezacaftor/ Elexacaftor in accordance with the resolution of 4 August 2022:)
>>
endobj
21 0 obj
<<
/Length 37
/Filter /FlateDecode
>>
stream
x+*23P0bdBr.KB W
endstream
endobj
22 0 obj
<<
/Length 809
/Filter /FlateDecode
>>
stream
HUn0+H"%J@ i=6hdc
GNN{lh0b>D!b[t12^kr HEآI,7M̐_tHt}3
N
,2aU!M fs